

TIME	ABSTRACT CODES	TITLE	LEAD AUTHOR	SESSION
FRIDAY, NOVEMBER 17				
ORAL PRESENTATION				
4:15 – 4:20 p.m. PT.	ACTR-27	Compliance and treatment duration predict survival in a phase III trial of tumor treating fields with temozolomide in patients with newly diagnosed glioblastoma	Ram, Z	Adult Clinical Trials - Non-Immunologic
POSTER PRESENTATION				
7:30 – 9:30 p.m. PT.	CBIO-30	Tumor treating fields (TTFields) inhibit cancer cell migration and invasion by inducing reorganizing of the actin cytoskeleton and formation of cell adhesions	Schneiderman, R	Cell Biology
7:30 – 9:30 p.m. PT.	CSIG-01	Tumor Treatment Fields downregulate specific transcription factors leading to reduced DNA repair capacity, increased replication stress, the inhibition of mitophagy and enhanced cell death	Story, M	Cell Signaling and Signaling Pathways
7:30 – 9:30 p.m. PT.	EXTH-04	Guiding principles for predicting the distribution of tumor treating fields in a human brain: A computer modeling study investigating the impact of tumor position, conductivity distribution and tissue homogeneity	Korshoej, AR	Experimental Therapeutics - Non-Immunological
7:30 – 9:30 p.m. PT.	EXTH-19	Combination of in vitro Tumor Treating Fields and temozolomide decrease proliferation in patient-derived glioblastoma cell lines	Michelhaugh, S	Experimental Therapeutics - Non-Immunological
7:30 – 9:30 p.m. PT.	EXTH-22	A new design for transducer arrays for the delivery of Tumor Treating Fields	Bomzon, Z	Experimental Therapeutics - Non-Immunological
7:30 – 9:30 p.m. PT.	EXTH-33	To achieve greater efficacy in tumor treatment fields: modeling based on the intracellular mechanisms	Carlson, K	Experimental Therapeutics - Non-Immunological
7:30 – 9:30 p.m. PT.	EXTH-45	The combination of TTFields and ABT-414 demonstrate superior efficacy against glioma cells	Schneiderman, R	Experimental Therapeutics - Non-Immunological
7:30 – 9:30 p.m. PT.	EXTH-66	Glioblastoma cells from a patient post-Tumor Treating Fields (TTFields) therapy are sensitive to TTFields in vitro	Michelhaugh, S	Experimental Therapeutics - Non-Immunological
7:30 – 9:30 p.m. PT.	EXTH-76	Optimizing transducer array configuration for treating tumors in the infratentorial and supratentorial brain using Tumor Treating Fields (TTFields)	Levi, S	Experimental Therapeutics - Non-Immunological
7:30 – 9:30 p.m. PT.	HOUT-06	TTFields for newly diagnosed Glioblastoma: Impact of consultation strategy	Proescholdt, M	Health Outcome Measures
7:30 – 9:30 p.m. PT.	NCOG-05	Time to functional and cognitive decline in a phase III trial of tumor treating fields with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma	Nicholas, G	Neuro-Cognitive Outcomes
7:30 – 9:30 p.m. PT.	NIMG-03	Quantitative MR measurements in glioblastoma patients: difference in mean diffusivity between Optune® patients and patients with only standard treatment	Vymazal, J	Neuroimaging
7:30 – 9:30 p.m. PT.	NIMG-18	Creating accurate computational head models of patients using dataset combining MRI and CT images	Naveh, A	Neuroimaging
7:30 – 9:30 p.m. PT.	NIMG-66	A method for rapidly creating head models of Glioblastoma patients for studying the delivery of TTFields to the brain	Urman, N	Neuroimaging
7:30 – 9:30 p.m. PT.	NIMG-67	Advanced perfusion and diffusion MR imaging in glioblastoma patients treated with Tumor Treating Fields (TTFields) as first-line therapy	Connelly, J. M	Neuroimaging
7:30 – 9:30 p.m. PT.	NIMG-92	Volumetric response to TTFields in newly diagnosed GBM	Freyschlag, CF	Neuroimaging
7:30 – 9:30 p.m. PT.	PALL-01	One year with Optune® in Austria: First report on clinical outcomes	Kerschbaumer, J	Supportive Palliative Care
7:30 – 9:30 p.m. PT.	PDCT-07	Tumor treating fields for pediatric patients with high grade glioma: first case series in Germany	Wolf, M	Pediatric Clinical Trials and Outcomes
7:30 – 9:30 p.m. PT.	QLIF-09	Long term Survival in Glioblastoma Patients After Tumor Treating Fields (TTFields) Therapy	Rulseh, A	Quality of Life
7:30 – 9:30 p.m. PT.	QLIF-16	Clinical and Social Challenges & Opportunities in Treating Glioblastoma with Tumor Treatment Fields, a Case Series	Nguyen, M	Quality of Life
7:30 – 9:30 p.m. PT.	QLIF-20	Skin care products compatible with Tumor Treating Fields	Lacouture, M	Quality of Life
7:30 – 9:30 p.m. PT.	QLIF-25	Effect of Tumor Treating Fields (TTFields) on health-related quality of life (HRQoL) in newly diagnosed glioblastoma. Results of the EF-14 randomized phase III trial	Taphoorn, M.J.B.	Quality of Life
7:30 – 9:30 p.m. PT.	QLIF-32	Meeting the patients - meeting the needs: Platforms for patients using Optune® to exchange expertise	Kebler, A. F	Quality of Life
7:30 – 9:30 p.m. PT.	QLIF-36	Role of nurses for the implementation of TTFields in daily clinical routine in glioblastoma treatment	Kilias, M	Quality of Life
7:30 – 9:30 p.m. PT.	QLIF-38	Tumor treating fields for the treatment of glioblastoma Multiforme in daily praxis: experience from two hospitals in Germany	May, S	Quality of Life
7:30 – 9:30 p.m. PT.	QLIF-42	Incidence and characterization of dermatologic adverse events in patients treated with Tumor Treating Fields and impact on overall survival	Sumrall, A	Quality of Life

TIME	ABSTRACT CODES	TITLE	LEAD AUTHOR	SESSION
SATURDAY, NOVEMBER 18				
ORAL PRESENTATION				
2:55 – 3:00 p.m. PT.	CBIO-16	Induction of autophagy following TTFields application serves as a survival mechanism mediated by AMPK activation	Shteingauz, A	Cell Biology
POSTER PRESENTATION				
5:00 – 7:00 p.m. PT.	ACTR-10	Patterns of TTFields-related severe skin toxicity in GBM patients	Leiberman, F	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-11	Overall survival in glioblastoma patients treated with Optune® correlates with compliance: consistency across studies	Potter, W	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-19	A Phase II study of Tumor Treating Fields and Bevacizumab in Recurrent or Progressive Meningioma	Kumthekar, P	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-20	Finding a predictive marker for compliance to TTFields therapy – the Comptune study	Proescholdt, M. A	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-24	The estimated long-term survival benefit of adding TTFields to the standard of care for glioblastoma patients	Guzauskas, G	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-29	A Phase II Study of TTFields and Pulsed Bevacizumab in Patients with Bevacizumab-refractory Recurrent Glioblastoma	Tran, D	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-39	Application of RTOG-RPA scores in a phase III trial of Tumor Treating fields with temozolomide (TTFields/TMZ) versus temozolomide (TMZ) alone in newly diagnosed glioblastoma	Choe, K	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-40	Stereotactic radiosurgery and tumor treating fields in small cell lung cancer patients with limited brain metastases: a pilot and feasibility trial	Dulaney, C	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-43	Tumor Treating Field compliance and overall survival in patients with primary GBM	Pandey, M	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-44	Autopsy study on the effects of tumor treatment fields in recurrent glioblastoma: preliminary results and trial design	Hurrell, S	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-49	The effect of tumor treating fields in WHO grade 2 and 3 gliomas	Blondin, N	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-54	Open-label phase I clinical trial testing Personalized and Targeted Intervention with skull remodeling surgery to Maximize Levels of TTFields intensity for higher treatment benefit - the OPTIMAL TTFields study	Korshoej, AR	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-55	Tumor treating fields with second line treatment compared to second line treatment alone in patients at first recurrence of glioblastoma – a post hoc analysis of the EF-14 phase 3 clinical trial	Kesari, S	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-62	A Phase II study of tumor treating fields (TTFields) with temozolomide in patients with low-grade gliomas	Juarez, T	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-65	Safety profile of tumor treating fields in adult glioblastoma patients with implanted non-programmable shunts, programmable shunts, and pacemakers/defibrillators: 6-year updated retrospective analysis of Optune® therapy.	Kew, Y	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-73	A phase II study of tumor treating fields in combination with bevacizumab and temozolomide in patients with newly diagnosed, unresectable glioblastoma	Sumrall, A	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ACTR-91	Numerical simulations of TTFields distribution in patient models reveals a connection between field intensity and patient outcome	Urman, N	Adult Clinical Trials - Non-Immunologic
5:00 – 7:00 p.m. PT.	ATIM-04	A Multi-Institutional Pilot Study of Prophylactic Cranial Tumor-Treating fields in patients with extensive-stage small cell lung cancer	Rana, N	Adult Clinical Trials - Immunologic
5:00 – 7:00 p.m. PT.	ATIM-07	Study of pembrolizumab, tumor treatment fields (Optune®) and temozolomide for older subjects with newly diagnosed glioblastoma	Donovan, L	Adult Clinical Trials - Immunologic
5:00 – 7:00 p.m. PT.	DDIS-15	Synergistic Inhibition of Glioma Cell Proliferation by Withaferin A and Tumor Treating Fields	Chang, E	Drug Discovery
5:00 – 7:00 p.m. PT.	IMMU-48	Evaluating the in-vitro effects of Tumor Treating Fields on T-cell responses	Diamant, G	Immunology
5:00 – 7:00 p.m. PT.	IMMU-59	Alternating electric fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy	Voloshin, T	Immunology
5:00 – 7:00 p.m. PT.	PDTM-26	Tumor Treating fields (TTFields) have anti-proliferative effects on pediatric brain tumor cell lines at clinically deliverable field settings	Smith, S	Pediatric Tumors-non-immunological
5:00 – 7:00 p.m. PT.	RARE-16	Case report: Delayed development of pseudoprogression in 2 glioblastoma patients treated with TTFields	Hurrell, S	Rare Tumors
5:00 – 7:00 p.m. PT.	RBIO-07	Tumor Treating Fields (TTFields) Delay DNA Damage Repair Following Radiation Treatment of Glioma Cells: Implications for Irradiation through TTFields Transducer Arrays	Giladi, M	Radiobiology
5:00 – 7:00 p.m. PT.	RTHP-04	Dosimetric impacts from a Tumor Treating Fields (ttfields) device for glioblastoma multiforme (GBM) patients undergoing simultaneous radiation therapy	LI, T	Radiation Therapy
5:00 – 7:00 p.m. PT.	RTHP-06	End-to-end workflow for finite element analysis of TTFields in Glioblastoma	Timmons, J	Radiation Therapy
5:00 – 7:00 p.m. PT.	RTHP-10	Impact of combination immunotherapy with Tumor Treating Fields therapy in a glioma cohort	Schulte, J	Radiation Therapy
5:00 – 7:00 p.m. PT.	RTHP-20	Radiation therapy targeting accuracy when combined with alternating electric field therapy	Grimm, J	Radiation Therapy
5:00 – 7:00 p.m. PT.	RTHP-26	Feasibility of a concomitant administration of alternating electric fields and radiotherapy - a planning study	Straube, C	Radiation Therapy
5:00 – 7:00 p.m. PT.	SURG-04	Cranial bone defects in patients treated with TTFields: A case series	Thon, N	Surgical Therapy
5:00 – 7:00 p.m. PT.	TMIC-38	Modulation of cancer cell metabolism and immune phenotype by TTFields	Wong, E	Tumor Microenvironment